Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda and HUTCHMED Limited announced that the European Medicines Agency has validated and accepted for regulatory review the marketing authorization application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors-1, -2, and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer.